A Randomized, Double-masked, Active Controlled, Parallel Group, Two-arm, Multi Center,in-vivo Bioequivalence Study with Clinical Endpoint Comparing Brinzolamide OphthalmicSuspension, USP 1 Percent of Riconpharma LLC, USA to AZOPT® (Brinzolamide OphthalmicSuspension) 1 Percent of Novartis Pharmaceuticals Corporation, USA in subjects with Chronic OpenAngle Glaucoma or Ocular Hypertension in both eyes - Nil

开始日期2024-08-06

申办/合作机构

RiconPharma LLC

CTRI/2023/06/054478

/ CompletedN/A

A multicenter, randomized, assessor-blinded, active controlled, parallel group, two arm, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml + Brimonidine tartrate 2 mg/ml eye drops suspension (AZAD Pharma AG, Switzerland) and Simbrinza® (Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml) eye drops suspension (Novartis Europharm Limited, Ireland ) in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

开始日期2023-07-25

申办/合作机构

AZAD Pharma AG

[+1]

EUCTR2022-002524-12-BG

/ Unknown status临床3期

A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml eye drops suspension (Brinzolamide 10mg/ml Eye Drops Suspension Preservative Free) as a test product versus AZOPT® 10 mg/ml eye drops suspension as reference product in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension

开始日期2023-04-13

申办/合作机构

AZAD Pharma AG

100 项与布林佐胺相关的临床结果

登录后查看更多信息

100 项与布林佐胺相关的转化医学

登录后查看更多信息

100 项与布林佐胺相关的专利（医药）

登录后查看更多信息

779

项与布林佐胺相关的文献（医药）

2025-07-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study

Article

作者: Kwan, Angela T H ; Popovic, Marko M ; Lakhani, Moiz ; Hurley, Bernard ; Mihalache, Andrew ; Muni, Rajeev H

PURPOSE:

Intraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients.

DESIGN:

Retrospective pharmacovigilance clinical cohort study.

METHODS:

This population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ² > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex.

RESULTS:

Of 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC₀₂₅ > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC₀₂₅ > 0), whereas these associations were not observed in males.

CONCLUSIONS:

This analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.

2025-05-01·EUROPEAN JOURNAL OF OPHTHALMOLOGY

Review: Clinical findings and genetic characterization of children affected with X-linked retinoschisis in the Spanish population

Review

作者: Coca Robinot, Javier Francisco ; Montaño, Victoria EF ; Noval Martín, Susana ; Peralta Calvo, Jesús ; Vallespín, Elena ; Arruti Vázquez, Natalia ; D’Anna Mardero, Oriana

X-linked retinoschisis (XLRS) is an inherited retinal disorder due to mutations in retinoschisin 1, characterized by impaired central vision secondary to parafoveal cystic cavities and visual field loss by splitting through the retinal nerve fibre layer in the peripheral retina. It is the leading cause of juvenile macular degeneration in males, and currently there is no approved treatment but carbonic anhydrase inhibitors can be used. A retrospective review of the medical records of 17 children with confirmed XLRS seen in the Paediatric Ophthalmology Department of La Paz University Hospital from the 1st of January 2009 to the 1st of June of 2023 was conducted. Complete ophthalmological studies, genetic testing and full-field electroretinogram were performed. Topical brinzolamide was given to patients with foveoschisis, adding oral acetazolamide in those who did not improve with topical treatment alone or with very extensive foveoschisis at diagnosis. Surgical treatment was performed in retinal detahment (RD) or in no clearing hemovitreous cases. Mean age at diagnosis was 5,86 years and the most common reason for consultation was strabismus, followed by RD. The most frequently affected retinal later on Optic coherence tomography was the inner nuclear layer and throughout the follow-up we observed a decrease in central macular thickness. We found some genotype-phenotype correlation in our series and more severe phenotypes if the first amino acid of the protein is affected or in frameshift mutations. We found that medical treatment (topical and oral) improves foveoschisis, and that surgery shows poor outcomes, especially in younger patients.

2025-05-01·MICROCHEMICAL JOURNAL

Simultaneous determination of brinzolamide, timolol maleate and its oxidative degradation product using univariate and multivariate green spectrophotometric methods

作者: Tantawy, Mahmoud A. ; Zaazaa, Hala E. ; Abd-ElSalam, Heba-Alla H. ; Nabil, Nada ; Mandour, Asmaa A. ; Naguib, Ibrahim A. ; Ibrahim, Mohamed A.

Spectrophotometric methods utilizing ratio-spectra were validated for simultaneous determination of Brinzolamide (BRZ) and Timolol maleate (TM) in the presence of the oxidative degradation product of TM (TM deg).TM deg interference was eliminated by dividing the zero-order absorption spectra of TM and BRZ by a concentration 20.00μg/mL of TM deg.The binary mixture was then analyzed via Method A which determined TM using a ratio difference spectrophotometric approach, where amplitude difference (ΔPA) of the TM spectra at 275.5 nm and 250.0 nm were used, as BRZ (ΔPA) was zero at these wavelengths.Method B involved adjusting the first derivative of the ratio spectra of BRZ and TM in order to determine BRZ selectively.When applying Δλ = 8, scaling factor = 10 and the maximum obtained at 243.8 nm, TM showed no contribution.Method C, involved dividing the total spectrum of the ternary mixture by a double divisor; the sum of the spectra of TM and TM deg.The amplitude of the first derivative of the resulting ratio spectra was measured at 243.7 nm to determine BRZ.Addnl., two multivariate methods, Partial Least Squares and Artificial Neural Networks were applied for determination of BRZ, TM and TM deg.Both models successfully determined BRZ, TM and TM deg.These methods were applied to analyze BRZ and TM in pharmaceutical formulations without matrix interference.Finally, the environmental sustainability of the proposed methods was evaluated.Two methods; National Environmental Methods Index and Eco-Scale assessment metric systems were utilized and revealed greenness of proposed methods.

项与布林佐胺相关的新闻（医药）

2024-05-10

·医药地理

“爱眼日”将近，重点眼病药品数据观察

2024年6月6日是第29个全国“爱眼日”。为进一步贯彻落实习近平总书记关于眼健康工作重要指示批示精神，切实推动《“十四五”全国眼健康规划（2021—2025年）》落到实处，充分调动社会各界积极性，提高人民群众爱眼护眼意识，国家卫健委于5月7日发布关于开展2024年全国“爱眼日”宣传教育周活动的通知。今年全国“爱眼日”宣传教育周活动主题为“关注普遍的眼健康”，活动将重点聚焦近视等屈光不正、白内障、眼底病、青光眼、角膜盲等重点眼病，着重关注儿童青少年、老年人两个重点人群，大力宣传全年龄段全生命周期眼健康的重要意义。本文我们将从重点眼病相关的药品数据出发，了解相关疾病和药品，关注眼健康。屈光不正当眼调节静止时，外界的平行光线经过眼睛的屈光系统，但不能在视网膜黄斑中心凹聚焦，因此无法产生清晰的成像，此种情况称为屈光不正（refractive error）或非正视（ametropia）。屈光不正包括近视、远视和散光。随着科技水平的发展及电子产品的普及，屈光不正在人群中，尤其是青少年中的发病率逐渐升高，且发病年龄逐渐减小。其中近视是最常见的屈光不正，影响近30%的人口。在PDB药物综合数据库中检索适应症为“屈光不正”的药品，常用的药品有康柏西普眼用注射液、复方尿维氨滴眼液、四味珍层冰硼滴眼液等。图：治疗屈光不正的药品销售额来源：PDB药物综合数据库，全渠道放大康柏西普（Conbercept）是一种抗血管内皮生长因子的融合蛋白，可以抑制病理性血管生成。康柏西普也是中国首个获得世界卫生组织国际通用名的、拥有全自主知识产权的生物I类新药，专利持有人为成都康弘生物科技有限公司（Chengdu Kanghong Biotechnologies Co. Ltd）。2021年，康柏西普全国销售额为15.94亿元，2022年销售额为13.66亿元，2023年Q1-Q3销售额为13.74亿元，推算全年销售额为18.28亿元，预计2024年销售额有望超过19亿元。图：康柏西普中国销售额来源：Pharma ONE智能药物大数据分析平台白内障白内障晶状体是人眼球中重要的光学部件，正常情况下是透明的。由于各种原因导致晶状体蛋白质变性而发生混浊，致使患者出现不同程度的视力下降，称为白内障（cataract）。全球盲人中因白内障致盲者约占46%，是全球第一位致盲性眼病。各型白内障中，最常见的是老年性白内障，多出现于50岁以上的中老年人。我国西藏地区白内障发病率最高，与紫外线的辐射有关。此外，随着生活水平的提高，糖尿病等代谢疾病的发病率逐年增加，白内障有逐渐低龄化的趋势。目前适应症为白内障的常用药物有注射用硫普罗宁、苄达赖氨酸滴眼液、氟米龙滴眼液、复明片等。图：治疗白内障的药品销售额来源：PDB药物综合数据库，全渠道放大硫普罗宁为一种新型含游离巯基的甘氨酸衍生物。能赋活代谢酶，并能和阻碍HS-酶活性的有毒物质相螯合，因而有解毒作用，可以升高白细胞并加速肝细胞的恢复，降低骨髓染色体畸变率和皮肤溃疡的发生。因此，硫普罗宁的临床应用较为广泛，在国内共涉及包括早期老年性白内障、酒精性脂肪肝、药物性肝损伤在内的13种疾病，在全球则扩大至19种疾病。图：硫普罗宁的在研适应症来源：Pharma ONE智能药物大数据分析平台氟米龙滴眼液属于皮质类固醇类抗炎药，可抑制由机械、化学或免疫原性等刺激因子导致的炎症。临床常用于治疗对皮质类固醇敏感的外眼部及眼前部组织的炎症，如眼睑炎、结膜炎、角膜炎及手术后炎症等。全球共有39家公司参与氟米龙药物开发，14家公司获批；国内则有19家公司参与氟米龙药物开发，6家公司获批。图：氟米龙滴眼液参与研发公司现状来源：Pharma ONE智能药物大数据分析平台青光眼青光眼是一组进行性视神经损害、最终损伤视力的疾病的统称，主要与病理性的眼压升高有关。青光眼是全球导致失明的第二大病因，仅次于白内障，却是第一位不可逆致盲眼病。预计到2020年，我国全人群青光眼患者将达到2182万（占全球27.4%），40岁以上人群患病率将达到3.05%，居世界首位。青光眼的治疗原则是降低患者的眼内压，主要治疗方式有滴眼药水、口服降眼压药物、激光治疗、手术等。常用药品有：布林佐胺滴眼液、拉坦前列腺素滴眼液、酒石酸溴莫尼定滴眼液等。图：治疗青光眼的药品销售额来源：PDB药物综合数据库，全渠道放大布林佐胺滴眼液是眼科常用的降低眼压的药物，属于一种碳酸酐酶抑制剂，通过抑制眼部睫状突的碳酸酐酶以减少眼球内部房水的分泌，或阻止碳酸氢盐离子的生成而减少钠/水转运，从而使眼压降低。目前，我国仅有1种布林佐胺滴眼液批准上市，生产企业为Novartis Europharm Ltd。图：布林佐胺滴眼液国内获批情况来源：CPM新药研发监测数据库拉坦前列素滴眼液为选择性前列腺素FP受体激动剂，通过增加房水流出而降低眼压，主要的临床适应证是开角型青光眼和高眼压症。2022年，拉坦前列素在中国销售额为1.32亿元人民币，包括拉坦前列素（1.25亿元人民币）和拉坦前列素+噻吗洛尔的复方制剂，全球销量10.56亿美元，单品销售额约7亿美元。图：2022年拉坦前列素销售额来源：Pharma ONE智能药物大数据分析平台总结图：2015-2023 眼科疾病治疗药品销售额来源：PDB药物综合数据库，全渠道放大上图为2015年至今的眼科疾病药品销售金额，从中可以看出眼科疾病用药总体呈增长趋势，其原因主要有两个：白内障、老年性黄斑病变等疾病与人口老龄化密切相关，过度的电子产品使用时长也使得年轻人眼病发生率提高。随着第29个全国“爱眼日”临近，也希望各位朋友多多了解眼健康常识，培养正确就医理念，提高儿童、老年人等重点人群早筛早诊早治意识，当好自己健康第一责任人，守护“眼健康”。END如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001

引进/卖出医药出海

2023-10-13

·PRNewswire

PADAGIS ANNOUNCES THE LAUNCH OF BRINZOLAMIDE OPHTHALMIC SUSPENSION WITH CGT EXCLUSIVITY

ALLEGAN, Mich., Oct. 13, 2023 /PRNewswire/ -- Padagis today announced the launch of Brinzolamide Ophthalmic Suspension with Competitive Generic Therapy (CGT) exclusivity (generic equivalent to the Reference Listed Drug Azopt® Ophthalmic Suspension). Azopt® Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers. Annual market sales for Azopt® were approximately $74 million in the 12 months ended August 2023 as measured by IQVIA. Padagis President, Pamela Hoffman, stated, "This launch and its accompanying CGT exclusivity demonstrates the ability of the Padagis team to bring complex generic products to the markets that need them. The Padagis team continues to leverage our unique and specialized technical and commercial capabilities to deliver important products to our customers and patients." About Padagis Padagis is dedicated to improving the well-being of patients and consumers by providing high quality, affordable, specialized healthcare products. The company is a leading provider of extended topical and other specialty pharmaceuticals to its primary markets of the United States and Israel. Padagis employs over 1,300 people worldwide. Visit Padagis online at (). SOURCE Padagis

2023-09-05

·BioBAY

研发动态丨海思盖德：国产微创青光眼引流系统完成首例临床手术

近日，BioBAY园内企业海思盖德在复旦大学附属眼耳鼻喉科医院“全国微创青光眼手术研究&培训中心”，完成首例PassCOGO®青光眼引流系统（睫畅®）产品临床入组。该产品属于微创术式下的房水引流管路重建术，在眼前房和结膜下建立新的房水引流通路，适用于降低单纯用药疗效不佳或不能耐受用药的青光眼患者的眼压，可实现对眼压的长期稳定控制，给国内众多的中重度青光眼患者带来福音。海思盖德于2020年在BioBAY成立，是一家致力于青光眼领域微创术式（Minimally Invasive Glaucoma Surgery, MIGS ）解决方案的全管线产品开发科技型企业，专注于研发和生产眼科疾病相关高端植入器械产品，是目前国内眼科MIGS细分赛道领域的头部企业。2020年11月，海思盖德成功入选苏州工业园区第十四届第二批科技领军人才；2022年获评“中国潜在独角兽企业”；2023年晋级“创业江苏”科技创业大赛省总决赛。青光眼是全球首位不可逆致盲眼病，据《中国青光眼指南（2020年）》数据显示，2020年全球原发性青光眼患病人数近8000万，中国患者超过2100万，是青光眼患者人数最多的国家。眼健康自2016年“十三五”规划就上升到国家战略高度，2022年“十四五”更是首次提出加强重点人群重点眼病防治，明确指出要提高青光眼的早诊早治能力。迄今为止，降低眼压仍是唯一被证实控制青光眼进展的有效手段，目前我国主要通过药物和手术进行眼压控制。近年来，MIGS因医生学习曲线低、损伤小、术后恢复快、相应的并发症少，且不影响后续实施传统滤过性手术，正在成为国际青光眼治疗的主流手段之一。此次手术由孙兴怀教授、孔祥梅教授团队完成临床植入，患者为62岁的女性，术眼为闭角型青光眼且于2022年行白内障超声乳化及人工晶体植入术联合房角分离术，术后一直使用布林佐胺和他氟前列素滴眼液降眼压治疗至今，术前平均眼压13.3mmHg，患者期望摆脱药物治疗。术前，团队根据患者的房角开放程度、过往药物使用情况进行了周密详尽探讨，并拟定了详细的手术方案，手术操作由孔祥梅主任执行。因PassCOGO®青光眼引流系统的便捷、精巧的设计，极大地降低了手术操作难度，该手术无需借助额外的大型设备，在院内常规眼科光学手术显微镜及房角镜辅助下即可完成。整个手术过程非常顺利，患者术后眼压13.1mmHg，仅进行抗炎治疗，无需使用降眼压药物。术后孙兴怀教授表示：此次临床手术的成功开展，标志着我国在国产微创青光眼引流系统产品研究应用领域开启新篇章。与此同时，这也是复旦大学附属眼耳鼻喉科医院“全国微创青光眼手术研究&培训中心”在一年内承担的第二款微创青光眼术式产品的临床研究。将有力推动MIGS术式产品在国内示范性、规范化和标准化操作，为树立行业规范奠定基础，并对进一步提高积累临床证据，规范临床研究，促进循证实践，整体提高我国青光眼治疗水平，缩小与欧美之间的差距。专家团队介绍孙兴怀复旦大学附属眼耳鼻喉科医院医学博士，主任医师，教授，博士生导师，现任中华医学会眼科学分会候任主委，国家卫健委/中国医科院近视眼重点实验室主任，复旦大学附属眼耳鼻喉科医院青光眼与视神经疾病学科主任，复旦大学上海医学院眼科学与视觉科学系主任，中国研究型医院学会眼科学与视觉科学专委会主委、亚太眼科学院院士、世界青光眼协会常务理事。荣获上海市科技精英，中华眼科杰出成就奖，中美眼科学会金苹果奖，亚太眼科协会（APAO）杰出贡献奖、国家科技进步奖二等奖等称号与奖项。陈君毅复旦大学附属眼耳鼻喉科医院医学博士，主任医师，博士生导师，现任中华医学会眼科学分会青年委员会委员，全国青光眼学组副组长，中国医师协会青光眼专业委员会委员，中国研究型医院学会眼科学分会委员，上海市医学会眼科学分会委员、青光眼学组组长，复旦大学附属眼耳鼻喉科医院眼科副主任、青光眼与视神经疾病学科常务副主任。孔祥梅复旦大学附属眼耳鼻喉科医院眼科博士，主任医师，博士生导师。复旦大学附属眼耳鼻喉科医院青光眼组成员。擅长各类青光眼的早期诊断以及药物、激光、手术治疗。2010年在美国Bascom Palmer眼科研究所做访问学者。多次在国际会议进行论文交流。▌文章来源：海思盖德，百拓生物责编：赵家帅审核：任旭推荐阅读研发动态丨澳宗生物：依达拉奉口服片剂ALS适应症关键临床已获美国FDA批准研发动态丨以诺康：重磅产品获批！国产眼科器械取得新突破研发动态丨AceLink：法布雷病患者2期临床研究在上海瑞金医院首家中心启动

临床结果ASCO会议临床研究放射疗法

100 项与布林佐胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00652	布林佐胺	S01EC04	DB01194

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Novartis Pharmaceuticals Corp.	2002-12-10
开角型青光眼	美国	Sandoz, Inc.	1998-04-01
高眼压症	美国	Sandoz, Inc.	1998-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05022004 (CTgov)	临床3期	开角型青光眼	599	Brinzolamide ophthalmic suspension (BRIN-20-01)	積簾簾構窪遞鑰齋衊築(網築築鑰獵鹽選鬱夢蓋) = 艱製築窪顧鹽鹹網蓋顧憲遞範遞範膚觸壓積憲 (鹹遞遞鹹鹹醖積願網艱, 2.290) 更多	-	2024-01-18
				Azopt® (Azopt®)	積簾簾構窪遞鑰齋衊築(網築築鑰獵鹽選鬱夢蓋) = 獵衊壓構遞襯窪願觸積憲遞範遞範膚觸壓積憲 (鹹遞遞鹹鹹醖積願網艱, 2.363) 更多
ARVO2023	N/A	一线	-	OcuSurf-BZ	憲淵淵壓鏇網製簾蓋衊(鏇醖獵遞蓋糧鹹觸衊襯) = 醖艱夢淵餘襯廠鹹淵積繭餘範鑰觸糧獵願遞繭 (遞鹹醖網醖簾壓遞蓋蓋 )	-	2023-04-23
NCT04024072 (CTgov)	临床3期	开角型青光眼	495	Brinzolamide 1% ophthalmic suspension (Perrigo Active)	夢獵壓艱膚願糧壓鏇鹽(窪範襯廠簾鬱廠遞膚夢) = 艱獵窪夢製齋遞餘窪遞製鬱醖積鑰遞醖積製製 (淵壓衊鏇觸鏇窪鑰餘觸, 2.713) 更多	-	2023-03-06
				Azopt 1% Ophthalmic Suspension (Reference Active)	夢獵壓艱膚願糧壓鏇鹽(窪範襯廠簾鬱廠遞膚夢) = 顧繭鬱窪壓襯鬱衊膚憲製鬱醖積鑰遞醖積製製 (淵壓衊鏇觸鏇窪鑰餘觸, 2.719) 更多
NCT03896633 (CTgov)	临床1/2期	开角型青光眼	637	brinzolamide 1% ophthalmic suspension (Brinzolamide 1% Ophthalmic Suspension)	遞膚齋廠膚獵夢窪選襯(簾齋壓繭網簾製廠鬱積) = 構範獵鑰範廠壓製衊構壓觸餘糧窪鹽遞積醖壓 (鑰繭遞餘繭範構壓鹹鏇, 3.269) 更多	-	2021-06-09
				Azopt 1% (Azopt 1% Ophthalmic Suspension)	遞膚齋廠膚獵夢窪選襯(簾齋壓繭網簾製廠鬱積) = 鹽積選憲製衊醖選鏇獵壓觸餘糧窪鹽遞積醖壓 (鑰繭遞餘繭範構壓鹹鏇, 3.183) 更多
NCT01722604 (CTgov)	临床3期	青光眼	258	brinzolamide 1% ophthalmic suspension (Brinzolamide 1% Ophthalmic Suspension)	願鹽齋簾選窪糧糧衊觸(積鬱鏇衊淵鏇獵鏇製鏇) = 衊艱夢鏇簾壓憲遞簾餘蓋網選襯製網廠鹹範廠 (窪淵繭艱夢製壓願淵積, 3.21) 更多	-	2021-06-09
				Azopt 1% (Azopt 1% Ophthalmic Suspension)	願鹽齋簾選窪糧糧衊觸(積鬱鏇衊淵鏇獵鏇製鏇) = 鏇製選淵糧蓋鬱範範築蓋網選襯製網廠鹹範廠 (窪淵繭艱夢製壓願淵積, 3.37) 更多
ARVO2020	N/A	-	-	brinzolamide (Intracameral administration)	艱築膚襯餘製鏇襯積艱(膚製膚壓膚淵夢構顧觸) = 選製憲顧構積顧網鏇製醖顧夢憲餘淵艱糧繭製 (積淵糧窪鹹簾範簾選簾 ) 更多	-	2020-06-01
NCT02512042 (CTgov)	临床3期	开角型青光眼	973	Reference-Brinzolamide 1% Ophthalmic suspension	鏇網蓋襯壓鹹餘膚遞壓(鏇夢夢遞選鬱膚鹽選鹹) = 築願膚壓鬱遞選築繭憲選願艱衊壓齋遞餘鹹網 (願醖艱觸鹹鹹鹹願製衊, 遞顧鏇築網衊廠遞糧觸 ~ 願醖齋夢簾鹽餘壓獵觸) 更多	-	2020-03-02
2019 ARVO Annual Meeting (ARVO2019)	N/A	视网膜变性 \| 黄斑变性	256	Alternate day topical brinzolamide	網膚蓋衊觸憲遞觸構壓(鬱鑰衊積願築淵積糧糧) = 獵蓋鏇憲蓋壓觸簾窪構襯廠鏇選襯顧遞築選觸 (糧壓蓋廠艱膚築製餘積, 82 ~ 128) 更多	-	2019-07-01
				Continuous topical brinzolamide	網膚蓋衊觸憲遞觸構壓(鬱鑰衊積願築淵積糧糧) = 憲夢醖襯淵範廠繭鹹鬱襯廠鏇選襯顧遞築選觸 (糧壓蓋廠艱膚築製餘積, 52 ~ 178) 更多
NCT01297517 (ARVO2014)	临床3期	低眼压	660	Fixed-Combination Brinzolamide 1%/Brimonidine 0.2%	繭製蓋遞憲鑰範鑰範顧(築鑰簾餘齋糧壓鏇艱網) = 積衊醖廠鑰繭繭網糧壓願願醖築鬱獵蓋艱夢網 (繭製淵網憲願願夢襯鹹, 2.97)	积极	2014-04-01
				Brinzolamide	繭製蓋遞憲鑰範鑰範顧(築鑰簾餘齋糧壓鏇艱網) = 積餘範鬱鏇選壓選製構願願醖築鬱獵蓋艱夢網 (繭製淵網憲願願夢襯鹹, 3.64)
ARVO2013	临床3期	-	690	Fixed-combination Brinzolamide 1%/Brimonidine 0.2%	願積膚積淵鑰鬱網鬱廠(簾構範獵窪範製鹹膚簾) = At 6 months, the most common treatment-related AEs for BBFC were eye irritation (6.3%), eye allergy (6.3%), and conjunctivitis (5.0%), for brinzolamide they were dysgeusia (10.3%) and blurred vision (6.8%), and for brimonidine they were conjunctivitis (6.0%) and conjunctivitis allergic (4.3%) 築積壓網淵夢蓋顧構鹽 (獵製網憲蓋簾鹹醖廠繭 )	积极	2013-06-01
				Brinzolamide